Your prediction
Takeda Pharmaceutical Co Ltd Stock
A loss of -1.910% shows a downward development for Takeda Pharmaceutical Co Ltd.
Our community identified positive and negative aspects for Takeda Pharmaceutical Co Ltd stock for the coming years. 1 users see the criterium "Business model" as a plus for the Takeda Pharmaceutical Co Ltd stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Takeda Pharmaceutical Co Ltd in the next few years
Pros
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Takeda Pharmaceutical Co Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Takeda Pharmaceutical Co Ltd | -1.910% | -4.465% | -1.513% | 22.400% | 17.062% | 1.023% | 5.517% |
| Chugai Pharmaceutical Co Ltd | -0.170% | -8.287% | -11.928% | 19.830% | 3.510% | 109.865% | 38.537% |
| Eisai Co Ltd | -0.180% | 1.405% | 6.791% | 27.376% | 10.392% | -45.698% | -49.732% |
| Santen Pharmaceutical Corp Ltd. | -2.010% | -1.515% | 8.939% | 21.875% | 12.069% | 30.000% | -14.474% |
Comments
News
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)
EQS-Adhoc: Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)